TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26559142
Drug: Medicine‐1st treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine‐1st treatment (IOP-lowering drops)
Study: 17031643
Drug: Doc-Gem (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doc-Gem (gemcitabine 900 mg/m² on days 1 and 8, docetaxel 75 mg/m² on day 1, every 3 weeks for up to six cycles)
Study: 17031643
Drug: Cis-Gem->Doc (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-Gem->Doc (gemcitabine 900 mg/m² on days 1 and 8, cisplatin 70 mg/m² on day 1 for three cycles, followed by docetaxel 100 mg/m² on day 1 for three cycles)
Study: 11235929
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean daily dose = 3.8 mg)
Study: 11235929
Drug: Pimozide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (mean daily dose = 2.9 mg)
Study: 25686338
Drug: Traditional ABCS
Normalized name: ABC
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional ABCS plus an extra intraoral suture at points G.lat.
Study: 19404210
Drug: XM02 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: XM02 (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Study: 19404210
Drug: Filgrastim Neupogen
Normalized name: filgrastim Injection [Neupogen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim Neupogen (5 microg/kg/d, subcutaneous daily injections for at least 5 days and a maximum of 14 days)
Study: 16894934
Drug: Compound Glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Glycyrrhizin for 6 months
Study: 11453879
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose heparinization (400 IU/kg) with standard uncoated ECC (Group A)
Study: 11453879
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose heparinization (400 IU/kg) with heparin-coated ECC (Group B)
Study: 11453879
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparinization (150 IU/kg) with heparin-coated ECC (Group C)
Study: 11453879
Drug: Heparin-coated ECC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated ECC with low dose systemic heparinization
Study: 1416135
Drug: alfentanil 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 30 micrograms/kg followed by propofol 2 mg/kg IV
Study: 1416135
Drug: alfentanil 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 40 micrograms/kg followed by propofol 2 mg/kg IV
Study: 1416135
Drug: alfentanil 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 50 micrograms/kg followed by propofol 2 mg/kg IV
Study: 1416135
Drug: alfentanil 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 60 micrograms/kg followed by propofol 2 mg/kg IV
Study: 1416135
Drug: d‐tubocurarine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine 3 mg, thiamylal 4 mg/kg, and succinylcholine 1 mg/kg IV (Group I)
Study: 29782065
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 25 mcg
Study: 17585664
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency pulse plus auricular point magnetic therapy
Study: 16225652
Drug: Continuous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous prednisolone treatment during the entire induction phase
Study: 16225652
Drug: Prednisolone given
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone given for 2 weeks of each cycle in combination with VMCP-IFN-alpha 2b
Study: 11872200
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d 17beta‐estradiol orally for 90 days
Study: 10211871
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intravenous (i.v.) infusion of zaleplon
Study: 10211871
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg intravenous (i.v.) infusion of zaleplon
Study: 10211871
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral dose of zaleplon
Study: 10211871
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous (i.v.) infusion of zaleplon
Study: 7796762
Drug: Chemotherapy, community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, community mobilization to effect change in water contact habits and faecal disposal
Study: 7192119
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 60 mg LCB-29
Study: 7192119
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 400 mg LCB-29
Study: 7192119
Drug: Ointment application
Normalized name: Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment application of 400 mg or 7 X 200 mg LCB-29
Study: 29402402
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum (200 mg) administered at 01:00 h, 03:00 h, 05:00 h, and 07:00 h during sleep deprivation
Study: 29402402
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum (200 mg)
Study: 28095883
Drug: Altitudes plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altitudes plus Specialist Treatment as Usual (STAU)
Study: 28095883
Drug: Specialist Treatment
Normalized name: Centrum Specialist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist Treatment as Usual (STAU) alone
Study: 25965709
Drug: Oral losmapimod
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral losmapimod (7.5 mg twice daily)
Study: 19689569
Drug: Born to
Normalized name: Born To Be Mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Born to Learn (BTL) curriculum conducted in monthly home visits
Study: 15319622
Drug: Hypotonic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic oral rehydration solution (ORS) with non-digestible carbohydrates (NDC)
Study: 15319622
Drug: Hypotonic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic oral rehydration solution (ORS) without non-digestible carbohydrates (NDC)
Study: 9590463
Drug: L-2-oxothiazolidine-4-carboxylic acid
Normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-2-oxothiazolidine-4-carboxylic acid (OTC) 1,500 mg
Study: 9590463
Drug: L-2-oxothiazolidine-4-carboxylic acid
Normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-2-oxothiazolidine-4-carboxylic acid (OTC) 3,000 mg
Study: 7929870
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral valproate after a 750 mg intravenous loading dose
Study: 7929870
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of valproate after a 750 mg loading dose
Study: 7929870
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous regimens
Study: 3300408
Drug: naloxone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 0.05 mg
Study: 29263150
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ezetimibe/simvastatin (E/S)
Study: 29263150
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg placebo/simvastatin
Study: 24037890
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of recombinant FSH (rFSH) pretreatment followed by 24 months of pulsatile GnRH therapy
Study: 24037890
Drug: Pulsatile GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile GnRH therapy alone for 24 months
Study: 12668982
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at 13-15 mg/kg/d for 6 months
Study: 10370357
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose ondansetron (0.6 mg/kg, maximum dose 32 mg)
Study: 10370357
Drug: Multiple standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple standard-dose ondansetron (0.15 mg/kg, maximum dose 8 mg, every 4 hr for four doses)
Study: 8911803
Drug: Sulfate-free electrolyte
Normalized name: Aminosyn 7 % with Electrolytes, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfate-free electrolyte lavage solution (SF-ELS)
Study: 8911803
Drug: Standard polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polyethylene glycol (PEG) solution
Study: 1867232
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 or 40 mg once or twice a day)
Study: 6617905
Drug: CC-hCG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-hCG plus dehydrogesterone (group 1)
Study: 6617905
Drug: CC-hCG (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-hCG (group 2)
Study: 28474286
Drug: Electronic tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic tablet animations
Study: 23865593
Drug: Feedback group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback group (receiving accelerometer-based feedback of daily walking activity)
Study: 21329631
Drug: heparin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 1,000 IU/ml
Study: 21329631
Drug: heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 5,000 IU/ml
Study: 15363874
Drug: Oral ibandronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate, 50mg once daily
Study: 11182748
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) started immediately after surgery
Study: 11182748
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during surgery and for 24 hours postoperatively
Study: 7997919
Drug: Functional restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional restoration program (treatment group)
Study: 3196530
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium 145 mEq/L
Study: 3196530
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium 150 mEq/L
Study: 3196530
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium 155 mEq/L
Study: 3196530
Drug: Dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate sodium 145 mEq/L to 155 mEq/L
Study: 31747355
Drug: Vitafusion® Power
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitafusion® Power C gummy (1000 mg)
Study: 31747355
Drug: Comparator caplet
Normalized name: Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator caplet (1000 mg)
Study: 30640777
Drug: Aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminolevulinic acid photodynamic therapy (ALA-PDT)
Study: 30640777
Drug: Vehicle photodynamic
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle photodynamic therapy (VEH-PDT)
Study: 25862116
Drug: 9‐mg sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9‐mg sustained release (SR) melatonin for four weeks
Study: 18283176
Drug: ABT‐874 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 200 mg once at week 0
Study: 18283176
Drug: ABT‐874 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 100 mg every other week for 12 weeks
Study: 18283176
Drug: ABT‐874 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 200 mg weekly for 4 weeks
Study: 18283176
Drug: ABT‐874 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 200 mg every other week for 12 weeks
Study: 18283176
Drug: ABT‐874 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 200 mg weekly for 12 weeks
Study: 12666468
Drug: Group Treatment
Normalized name: Heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Treatment Control (GC)
Study: 10968599
Drug: Intravaginal clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal clindamycin cream
Study: 8940218
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of conjugate heptavalent pneumococcal vaccine
Study: 8940218
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of conjugate heptavalent pneumococcal vaccine
Study: 8940218
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 23‐valent native polysaccharide vaccine
Study: 8940218
Drug: Conjugate pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugate pneumococcal vaccine
Study: 1347191
Drug: Sufentanil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (50 micrograms in 60 ml normal saline)
Study: 1347191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine 0.125% and sufentanil (50 micrograms in 60 ml bupivacaine 0.125%)
Study: 3886154
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (825 mg initial dose followed by 550 mg if symptoms persisted)
Study: 25092702
Drug: Dihydroartemisinin-piperaquine (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (180 mg dihydroartemisinin and 1,440 mg piperaquine administered as two consecutive daily doses once per month for a planned 4-month period)
Study: 22538450
Drug: MMF-withdrawal (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF-withdrawal (target area under the time-concentration curve-cyclosporine: 3250 ng·hr/mL)
Study: 22538450
Drug: CNI-withdrawal (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-withdrawal (target area under the time-concentration curve-mycophenolic acid: 75 μg·hr/mL)
Study: 17514671
Drug: Single-dose antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antimicrobial prophylaxis
Study: 17514671
Drug: Multiple-dose antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose antimicrobial prophylaxis
Study: 12032113
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (10 units)
Study: 12032113
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (10 units)
Study: 12032113
Drug: Intermediate-acting human
Normalized name: Intermediate-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-acting human insulin (bedtime injection)
Study: 8016794
Drug: NCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCPAP treatment
Study: 2739867
Drug: Oral VUEFFE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral VUEFFE (VF)
Study: 4596491
Drug: Monovalent classical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent classical Ogawa vaccine
Study: 4596491
Drug: Monovalent Inaba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent Inaba vaccine
Study: 4596491
Drug: Monovalent El
Normalized name: hydroxypropyl cellulose (type EL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent El Tor vaccines (not specified)
Study: 4596491
Drug: Monovalent classical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent classical Inaba vaccine
Study: 30953333
Drug: roxadustat 50
Normalized name: Roxadustat 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat 50 mg TIW
Study: 30953333
Drug: roxadustat 70
Normalized name: Roxadustat 70 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat 70 mg TIW
Study: 30953333
Drug: roxadustat 100
Normalized name: Roxadustat 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxadustat 100 mg TIW
Study: 28726169
Drug: Clonidine mucoadhesive
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine mucoadhesive buccal tablet (MBT) 50 and 100 µg
Study: 28726169
Drug: Clonidine mucoadhesive
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine mucoadhesive buccal tablet (MBT)
Study: 28726169
Drug: Reference clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference clonidine oral tablet (OT)
Study: 19339887
Drug: Recent advancements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent advancements in RCC treatments
Study: 11329233
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 5 mg/d for 13 days, for 9 months
Study: 9416890
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or placebo (treatment arm)
Study: 8495311
Drug: Cefazolin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin, 500 mg every 8 hours for 24 hours
Study: 3122113
Drug: Modified Goeckerman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Goeckerman treatment
Study: 28103831
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment for BRVO
Study: 28103831
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment for CRVO
Study: 12508388
Drug: IV doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV doxycycline 300 mg/day for 14 days
Study: 8952749
Drug: Strategies for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies for prevention and treatment of bone loss in lupus patients; specific interventions not detailed.
Study: 8952749
Drug: Prevention of
Normalized name: Humanized IGG4 monoclonal antibody against toll-like receptor 2 for prevention of ischemia/reperfusion tissue injury
DrugBank: Tomaralimab (DB15415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention of steroid-induced bone loss; specific interventions not detailed.
Study: 8952749
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of gonadal effects of cytotoxic agents; specific interventions not detailed.
Study: 30869820
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy with a written checklist (Group II)
Study: 30869820
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with a written checklist (Group IV)
Study: 30869820
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment plus behavioral therapy without a checklist (Group III)
Study: 30869820
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy as a written guideline (Group I)
Study: 28003539
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400 mg daily from 18-22 weeks of gestation to delivery)
Study: 19954716
Drug: Gliclazide/metformin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide/metformin combination tablet (80/500 mg)
Study: 19954716
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of gliclazide (80 mg) and metformin (500 mg) as individual tablets
Study: 17355215
Drug: Novel compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel compounds under investigation for heart failure treatment
Study: 10490152
Drug: Procaine with
Normalized name: penicillin G procaine with aluminum stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine with 0.3 mg epinephrine (EPI group)
Study: 10490152
Drug: Procaine with
Normalized name: penicillin G procaine with aluminum stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine with 0.3 ml NaCl 0.9% (SALINE group)
Study: 8944409
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg with fluvoxamine (mean dose 127 mg/day)
Study: 1742482
Drug: GM-CSF (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (1.0 microgram/kg/d, increased as needed) with full-dose zidovudine (1,200 mg/d)
Study: 6896183
Drug: Tolamolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol 200 mg
Study: 26477496
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or 10 mg daily ulipristal acetate for four repeated 12‐week treatment courses
Study: 24249538
Drug: 6-monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-monthly follow-up
Study: 24249538
Drug: 3-monthly follow-up
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-monthly follow-up
Study: 8580277
Drug: Fluconazole oral
Normalized name: fluconazole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole oral suspension (200 mg loading dose followed by 100 mg q.d.s. for 2 weeks after symptom resolution)
Study: 19292590
Drug: efavirenz-based triple
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz-based triple combination therapy
Study: 11301568
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B complex capsules (fursulthiamine 50 mg, hydroxocobalamin 250 micrograms, pyridoxal phosphate 30 mg, and riboflavin 5 mg)